Enjoy complimentary customisation on priority with our Enterprise License!
The schizophrenia drugs market share should rise by USD 957.50 million from 2021 to 2025 at a CAGR of 2.06%.
This market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentations by drug class (second-generation antipsychotic drugs, third-generation antipsychotic drugs, and first-generation antipsychotic drugs) and geography (North America, Europe, Asia, and ROW). The market report also offers information on several market vendors, including AbbVie Inc., Alkem Laboratories Ltd., Alkermes Plc, AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim International GmbH, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Johnson and Johnson Inc., and Otsuka Holdings Co. Ltd. among others.
To Unlock the Market Size for 2021 and Other Important Statistics, Download the Free Report Sample!
The increasing expenditure on prescription drugs is notably driving the market growth, although factors such as lack of standard diagnostic methods may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the market. The holistic analysis of the drivers will help in predicting end goals and refining marketing strategies to gain a competitive edge.
This market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
The vendor landscape of the market entails successful business strategies deployed by the vendors. The market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Download a free sample of the market forecast report for insights on complete key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
For more insights on the market share of various regions Request for a FREE sample now!
40% of the market's growth will originate from North America during the forecast period. The US is the key market for schizophrenia drugs in North America.
The report offers an up-to-date analysis of the geographical composition of the market. North America has been recording a significant growth rate and is expected to offer several growth opportunities to market vendors during the forecast period. Increasing awareness programs will facilitate market growth in North America over the forecast period. The report offers an up-to-date analysis of the geographical composition of the market, competitive intelligence, and regional opportunities in store for vendors.
To gain further insights on the market contribution of various segments Request for a FREE sample
The market share growth by the second-generation antipsychotic drugs segment has been significant. This report provides insights on the impact of the unprecedented outbreak of COVID-19 on market segments. Through these insights, you can safely deduce transformation patterns in consumer behaviour, which is crucial to gauge segment-wise revenue growth during 2021-2025 and embrace technologies to improve business efficiency.
This report provides an accurate prediction of the contribution of all the segments to the growth of the market size. Furthermore, our analysts have indicated actionable market insights on post COVID-19 impact on each segment, which is crucial to predict change in consumer demand.
|
Schizophrenia Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 2.06% |
|
Market growth 2021-2025 |
$ 957.50 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
1.75 |
|
Regional analysis |
North America, Europe, Asia, and ROW |
|
Performing market contribution |
North America at 40% |
|
Key consumer countries |
US, Germany, UK, China, and Japan |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Companies profiled |
AbbVie Inc., Alkem Laboratories Ltd., Alkermes Plc, AstraZeneca Plc, Biogen Inc., Boehringer Ingelheim International GmbH, Dr. Reddys Laboratories Ltd., Eli Lilly and Co., Johnson and Johnson Inc., and Otsuka Holdings Co. Ltd. |
|
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
Executive Summary
Market Landscape
Market Sizing
Five Forces Analysis
Market Segmentation by Drug class
Customer landscape
Geographic Landscape
Vendor Landscape
Vendor Analysis
Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
